Endovascular Engineering, a commercial-stage medical technology company focused on advancing the treatment of venous thromboembolism (VTE), announced an oversubscribed $80 million Series C financing co-led by Gilde Healthcare and Norwest, with participation from existing investors including Sante Ventures, 415 Capital, S3 Ventures, Panakes Partners, M&L Healthcare Investments, as well as the two existing undisclosed strategic investors and a new global strategic investor.